L'immunoterapia specifica con allergeni inalanti

Translated title of the contribution: Specific immunotherapy with inhalant allergens

C. Incorvaia, G. Passalacqua, A. Fiocchi, G. Colombo, M. Landi, S. Tripodi, G. W. Canonica

Research output: Contribution to journalArticle

Abstract

Allergen specific immunotherapy is the only treatment acting on the causes and not only on the symptoms of respiratory allergy, including rhinitis and asthma. Currently, this therapy can be performed by two routes of administration, that is, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Both forms have sound demonstration of clinical efficacy, based on several meta-analyses, but SCIT is partially limited by the problem of safety, because, though rarely, severe systemic reactions may occur, while SLIT has a very satisfactory safety profile. The mechanim of action is similar in both forms, consisting in modifications, through allergen presentation by antigen presenting cells, of the T lymphocytes response and their cytokine pattern. In fact, from the Th2 prevalence typical of allergic inflammation the subjects treated with immunotherapy show a Th1 prevalence and an influence by T-regulatory cells. The future developments are likely to be based on new materials as well as on new routes of administration, such as the epicutaneous route and the intra-lymphonodal route, that in preliminary studies appeared promising.

Original languageItalian
Pages (from-to)1-20
Number of pages20
JournalItalian Journal of Allergy and Clinical Immunology
Volume22
Issue number1-2
Publication statusPublished - 2012

Fingerprint

Sublingual Immunotherapy
Immunotherapy
Allergens
Immunologic Desensitization
Safety
Antigen-Presenting Cells
Regulatory T-Lymphocytes
Rhinitis
Meta-Analysis
Hypersensitivity
Asthma
Cytokines
Inflammation
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Incorvaia, C., Passalacqua, G., Fiocchi, A., Colombo, G., Landi, M., Tripodi, S., & Canonica, G. W. (2012). L'immunoterapia specifica con allergeni inalanti. Italian Journal of Allergy and Clinical Immunology, 22(1-2), 1-20.

L'immunoterapia specifica con allergeni inalanti. / Incorvaia, C.; Passalacqua, G.; Fiocchi, A.; Colombo, G.; Landi, M.; Tripodi, S.; Canonica, G. W.

In: Italian Journal of Allergy and Clinical Immunology, Vol. 22, No. 1-2, 2012, p. 1-20.

Research output: Contribution to journalArticle

Incorvaia, C, Passalacqua, G, Fiocchi, A, Colombo, G, Landi, M, Tripodi, S & Canonica, GW 2012, 'L'immunoterapia specifica con allergeni inalanti', Italian Journal of Allergy and Clinical Immunology, vol. 22, no. 1-2, pp. 1-20.
Incorvaia C, Passalacqua G, Fiocchi A, Colombo G, Landi M, Tripodi S et al. L'immunoterapia specifica con allergeni inalanti. Italian Journal of Allergy and Clinical Immunology. 2012;22(1-2):1-20.
Incorvaia, C. ; Passalacqua, G. ; Fiocchi, A. ; Colombo, G. ; Landi, M. ; Tripodi, S. ; Canonica, G. W. / L'immunoterapia specifica con allergeni inalanti. In: Italian Journal of Allergy and Clinical Immunology. 2012 ; Vol. 22, No. 1-2. pp. 1-20.
@article{6d6d8b19113e456a9783eb96e346524d,
title = "L'immunoterapia specifica con allergeni inalanti",
abstract = "Allergen specific immunotherapy is the only treatment acting on the causes and not only on the symptoms of respiratory allergy, including rhinitis and asthma. Currently, this therapy can be performed by two routes of administration, that is, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Both forms have sound demonstration of clinical efficacy, based on several meta-analyses, but SCIT is partially limited by the problem of safety, because, though rarely, severe systemic reactions may occur, while SLIT has a very satisfactory safety profile. The mechanim of action is similar in both forms, consisting in modifications, through allergen presentation by antigen presenting cells, of the T lymphocytes response and their cytokine pattern. In fact, from the Th2 prevalence typical of allergic inflammation the subjects treated with immunotherapy show a Th1 prevalence and an influence by T-regulatory cells. The future developments are likely to be based on new materials as well as on new routes of administration, such as the epicutaneous route and the intra-lymphonodal route, that in preliminary studies appeared promising.",
author = "C. Incorvaia and G. Passalacqua and A. Fiocchi and G. Colombo and M. Landi and S. Tripodi and Canonica, {G. W.}",
year = "2012",
language = "Italian",
volume = "22",
pages = "1--20",
journal = "Italian Journal of Allergy and Clinical Immunology",
issn = "1120-6373",
publisher = "Italian Society of Allergy and Clinical Immunology",
number = "1-2",

}

TY - JOUR

T1 - L'immunoterapia specifica con allergeni inalanti

AU - Incorvaia, C.

AU - Passalacqua, G.

AU - Fiocchi, A.

AU - Colombo, G.

AU - Landi, M.

AU - Tripodi, S.

AU - Canonica, G. W.

PY - 2012

Y1 - 2012

N2 - Allergen specific immunotherapy is the only treatment acting on the causes and not only on the symptoms of respiratory allergy, including rhinitis and asthma. Currently, this therapy can be performed by two routes of administration, that is, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Both forms have sound demonstration of clinical efficacy, based on several meta-analyses, but SCIT is partially limited by the problem of safety, because, though rarely, severe systemic reactions may occur, while SLIT has a very satisfactory safety profile. The mechanim of action is similar in both forms, consisting in modifications, through allergen presentation by antigen presenting cells, of the T lymphocytes response and their cytokine pattern. In fact, from the Th2 prevalence typical of allergic inflammation the subjects treated with immunotherapy show a Th1 prevalence and an influence by T-regulatory cells. The future developments are likely to be based on new materials as well as on new routes of administration, such as the epicutaneous route and the intra-lymphonodal route, that in preliminary studies appeared promising.

AB - Allergen specific immunotherapy is the only treatment acting on the causes and not only on the symptoms of respiratory allergy, including rhinitis and asthma. Currently, this therapy can be performed by two routes of administration, that is, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Both forms have sound demonstration of clinical efficacy, based on several meta-analyses, but SCIT is partially limited by the problem of safety, because, though rarely, severe systemic reactions may occur, while SLIT has a very satisfactory safety profile. The mechanim of action is similar in both forms, consisting in modifications, through allergen presentation by antigen presenting cells, of the T lymphocytes response and their cytokine pattern. In fact, from the Th2 prevalence typical of allergic inflammation the subjects treated with immunotherapy show a Th1 prevalence and an influence by T-regulatory cells. The future developments are likely to be based on new materials as well as on new routes of administration, such as the epicutaneous route and the intra-lymphonodal route, that in preliminary studies appeared promising.

UR - http://www.scopus.com/inward/record.url?scp=84869817373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869817373&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:84869817373

VL - 22

SP - 1

EP - 20

JO - Italian Journal of Allergy and Clinical Immunology

JF - Italian Journal of Allergy and Clinical Immunology

SN - 1120-6373

IS - 1-2

ER -